Back New Episode of QuickConversations Provides Solutions for Keeping Clinical Trials and Medical Research Moving During COVID-19 Pandemic
New York, NY June 26, 2020 -- The Quick Group has just launched another episode of their QuickConversations podcast, designed to help the life science and medical research community keep their global clinical trials moving during the pandemic – utilizing best practices and proven patient-centric solutions.
The COVID-19 crisis is continuing its dramatic impact on lives globally. But in life sciences, even during a pandemic, patients who are being treated for non-COVID-19 illnesses still need to receive their treatments. Clinical trials must move forward. And medical supply chains have to be kept intact.
And while the virus continues, many companies around the world have quickly switched their focus to the development of a COVID-19 vaccine. The usually fast-paced world of life science logistics is now moving even faster.
In the latest QuickConversations episode, QuickSTAT’s Scott Ohanesian, SVP of Commercial Operations, North America shares how QuickSTAT has been meeting the challenges faced by their pharma and biotech clients since the onset of the current healthcare crisis. Scott shares :
What goes into supporting logistics for clinical trials when confronted by so many pandemic-created obstacles?
The solutions that help companies adhere to trial protocols, keep patients safe and ensure their therapies are received on time.
Best logistics practices for overcoming an array of challenges -- government regulations, severely reduced airline schedules and dire economic situations.
“We’re proud of this podcast and to share the expertise of Scott – particularly now, as life science companies are grappling with the challenges caused by the pandemic. We’re happy to offer logistics solutions to our pharmaceutical and biotech clients in order to keep their clinical trials in process during this unprecedented time. All of us at QuickSTAT never forget that it’s not just about moving a box or a package, there’s a patient that it’s going to have an impact on,” says Cyril Leger, Executive Vice President, QuickSTAT.